Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lomustine With and Without Reirradiation for First Progression of Glioblastoma
NCT05904119Phase 3Recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Mar 2024
- Primary completion
- Sep 2027
- Modality
- DNA Intercalators/Alkylators
- Countries
- 11
01
Overview
A Phase 3 trial of lomustine in glioblastoma (GBM), sponsored by European Organisation for Research and Treatment of Cancer. Started Mar 2024; status: recruiting.
02
Drugs
lomustine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05904119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05904119.